Key Takeaways
- Shares of Ultragenyx plummeted 45% in after-hours trading following negative Phase 3 results for apazunersen in Angelman syndrome
- The experimental therapy failed to achieve its primary endpoint and crucial secondary endpoint in the Aspire clinical trial
- Researchers observed no significant distinctions between the treatment group and placebo recipients
- The disappointing outcome raises serious concerns about the companion Aurora trial currently underway
- The biotech firm intends to reduce operational costs while focusing on its marketed products, including the newly approved Genglycos gene therapy
Shares of Ultragenyx Pharmaceutical (RARE) plummeted 45% during Wednesday’s extended trading session following the announcement that apazunersen, its investigational treatment, failed to demonstrate efficacy in a pivotal Phase 3 clinical study for Angelman syndrome.
Ultragenyx Pharmaceutical Inc., RARE
The clinical study, designated as Aspire, evaluated apazunersen’s potential to enhance cognitive and developmental functioning in pediatric patients diagnosed with this rare genetic disorder. The therapy failed to achieve improvement in the primary endpointāmeasured by changes in Bayley-4 cognitive raw scoresāand also missed the critical secondary endpoint, which assessed net response using the Multidomain Responder Index (MDRI).
According to Ultragenyx, the data revealed no statistically significant or clinically meaningful distinctions between participants receiving apazunersen and those in the placebo cohort. While the therapy’s safety profile aligned with previous studies, this provided minimal reassurance to stakeholders.
Chief Executive Officer Emil Kakkis expressed his disappointment with the outcome, emphasizing the impact on patients and their families who had placed considerable hope in the therapy. “We are disappointed for the global patient community who has invested so much in early-stage research,” he stated.
Angelman syndrome is an extremely rare neurogenetic disorder that occurs in approximately 1 out of every 15,000 births, resulting from the absence of functional UBE3A gene expression. The condition manifests through intellectual disability, epileptic seizures, and profound developmental challenges. To date, no disease-modifying therapies have received regulatory approval for this indication.
Implications for the Ongoing Aurora Trial
The Aspire trial’s negative outcome casts significant uncertainty over Aurora, an ongoing companion study evaluating apazunersen in Angelman syndrome patients presenting with distinct genetic mutation patterns.
Analyst Sami Corwin from William Blair observed that even if the Aurora trial demonstrates positive results for its primary endpoint, the path to successful commercialization would face substantial obstacles. According to Corwin, the eligible patient population is insufficiently large to sustain a commercially feasible product.
The investigational drug had previously been granted multiple regulatory designations from the FDA, including both Breakthrough Therapy and Orphan Drug classifications. These recognitions stemmed from encouraging signals observed in earlier Phase 1 and Phase 2 trials, which makes the Phase 3 disappointment particularly striking for investors and the medical community.
Ultragenyx announced plans to conduct a comprehensive evaluation of the apazunersen development program to determine future strategic decisions. The company also indicated it would initiate cost-reduction measures as part of a broader operational reassessment.
Company Pivots Focus to Commercial Portfolio
Notwithstanding this significant clinical setback, Ultragenyx highlighted its expanding portfolio of marketed products as a foundation for continued business operations.
In recent weeks, the biotechnology company secured FDA authorization for Genglycos, a novel gene therapy designed to treat glycogen storage disease type Ia, commonly referred to as Von Gierke disease. This approval marked a historic milestone as the first gene therapy cleared for this metabolic disorder.
Additionally, the company anticipates a regulatory decision on UX111 for Sanfilippo syndrome and continues geographical expansion efforts for its existing commercial products. CEO Kakkis affirmed that the organization maintains its trajectory toward achieving profitability by 2027.
The Aspire trial recruited participants whose baseline clinical characteristics closely matched those enrolled in the Phase 2 study, making the contrasting results particularly difficult to interpret and intensifying investor concerns.
Ultragenyx emphasized its commitment to sustaining its commercial operations while undertaking a strategic review of its development pipeline in response to the apazunersen trial outcome.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
